Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin Intensification in Allo-SCT Conditioning
NCT00002989Phase 3Unknown
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 1997
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of idarubicin in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS), sponsored by European Organisation for Research and Treatment of Cancer. Status: unknown.
02
Drugs
idarubicin
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00002989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002989.